40 Jahre Insulin und intermedi�rer Stoffwechsel

Staub, H.

doi:10.1007/bf01485774

Cited by 6 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die einfache intravenöse Glucosebelastung und die Ermittlung der Halbwertszeit der Glucose (Τ) sind in Abbildung 1 schematisch dargestellt. Die von uns untersuchten Patienten ließen sich nach der Größe des ko-Wertes der ersten intravenö sen Glucosebelastung in fünf Gruppen einteilen: 1. erhöhte kG-Werte (über 2,2), 2. normale kG-Werte (1,2), 3. Zwischenbereich (k G : 1,0-1,2), 4. er niedrigte kG-Werte (unter 1,0) ohne Glykosurie (= latent diabetisch), 5. erniedrigte kc-Werte (un ter 1,0) mit Glykosurie (= manifest diabetisch).…”

Section: Verhandtungsberichteunclassified

Vergleich klinischer Methoden zur Erfassung des latenten Diabetes mellitus^*¹

Scriba¹,

Schwarz²,

Hofmann³

1966

Dtsch med Wochenschr

View full text Add to dashboard Cite

show abstract

Section: Verhandtungsberichteunclassified

Vergleich klinischer Methoden zur Erfassung des latenten Diabetes mellitus^*¹

Scriba¹,

Schwarz²,

Hofmann³

1966

Dtsch med Wochenschr

View full text Add to dashboard Cite

show abstract

“…of 165,62. Since 1957, when the "second life" of the biguanides started (2) to reach nowdays about 200 million doses/day worldwide for treatment of overweight persons with diabetes type II alone or in combination with other orally administered antidiabetic compounds or with insulin (3).Many elderly diabetics type 2 suffer from hypertension and also take diuretics and other antihypertensive medication in addition to metformin (4).…”

Section: Introductionmentioning

confidence: 99%

From Synthalin to Metformin:is a Century Cycle of Biguanides as Oral Antidiabetic drugs Now Closed?

Ramadori¹

2023

Preprint

View full text Add to dashboard Cite

After the first release of synthalin B (dodecamethylenbiguanide) in 1928 and its later retraction in the 1940s in Germany and the retraction of phenformin (N-Phenethylbiguanide) because of the letal complication of acidosiss,metformin (1-1-dimethylbiguanide) was first released in France in 1959 and then in the USA in 1995 for oral treatment of diabetes type 2. Acute gastrointestinal side effects often lead to dose reduction and strongly limit adherence to therapy.Main long-term consequences are deficency of vitamin B12 and of iron and sometimes also acidosis development. Intravenously injected F18-labelled glucose in metformin-treated type 2 diabetics accumulates in the the small and even more in the large intestine.The densitometry picture observed in metformin-treated diabetics is similar to that observed in patients after bowel-cleansing or chronically taking different types of laxatives where the accumulated radioactivity can even reach values observed in colon cancer. The glucose-lowering mechanism of action of metformin is therefore not only due to inhibition of glucose uptake in the small intestine but also to „attraction“ of glucose from the hepatocyte to the intestine,possibly through its secretion into the bile.Metformin is not different from the other biguanides ,synthalin B and phenformin.The mechanism of action,and the side effects are comparable to those of laxatives.

show abstract